Why a universal antiretroviral regimen?

Citation: Flexner CW, Clayden P, Venter WDF. Why a universal antiretroviral regimen? Curr Opin HIV AIDS. 2017 Jul;12(4):315-317. doi: 10.1097/COH.0000000000000390. PMID: 28486340. PMCID: PMC5722220.

Access full article:

https://www.ncbi.nlm.nih.gov/pubmed/28486340

In 2015, with its "Treat all" recommendation, World Health Organization (WHO) removed all restrictions on eligibility for antiretroviral treatment (ART) among HIV positive people. WHO estimates that by the end of 2018, 20 million people worldwide will be receiving combination ART. An additional 15–17 million will be in need of ART but unable to access or afford it [1]. Most of the existing supply of antiretrovirals (ARVs) is provided through international agencies, such as PEPFAR and the Global Fund, or governments of low- and middle-income countries (LMICs), all of which face stable or shrinking health care budgets.

The economic challenges facing global provision of ARVs alone represent an overwhelming barrier to full treatment access. When combined with the logistical and implementation barriers, civil unrest, increasing ARV drug resistance worldwide, and continued issues with stigma in many parts of the world, it is hard to imagine how the treatment needs of all people with HIV can be met with existing programs and resources.

Categories

CRS
Topics

Clinical Trials

A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...

Read More

A5329: Interferon –Free Therapy for Chronic Hepatitis C...

A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...

Read More

A5300B/I2003B/PHOENIX, Protecting Households On Exposure to...

This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...

Read More

P2001 (DAIDS ID 12026): Evaluating the Pharmacokinetics,...

TB is a major cause of illness and death in women of reproductive age. Pregnant and postpartum women with latent TB are at...

Read More

IMPAACT 2034 - Phase I Study of the Pharmacokinetics,...

This is a Phase I, multi-site, open-label, non-comparative study of the PK, safety, tolerability, and acceptability of a...

Read More